GreenLight HPS™

Laser Therapy System

GreenLight™ Laser Therapy is setting the new standard with equivalent clinical outcomes to TURP, fewer serious adverse events, shorter recovery and lower overall hospital costs.1

Key Resources

Improving the lives of patients with BPH

The clinical benefits of the GreenLight™ Laser Therapy experience in treating benign prostatic hyperplasia (BPH) have been well documented in over 1,000 publications.2 Boston Scientific routinely reviews the scientific literature to keep up-to-date on the latest clinical evidence available regarding the safety and efficacy of GreenLight therapy.

From all of the research we’ve collected, it has been shown that GreenLight Laser Therapy has1:

  • Equivalent outcomes to transurethral resection of the prostate (TURP)
  • Fewer serious adverse events
  • Shorter patient recovery
  • Faster return to stable health

 Plus, GreenLight Laser Therapy may be a more cost-effective treatment option.


What the literature says

The table below uses the results of several studies in which GreenLight therapy was used for the treatment of BPH. Based on this analysis, GreenLight therapy has been demonstrated to provide a number of clinical benefits.

Summary of GreenLight Laser Therapy Randomized Controlled Trials3

Study

 

Number of GreenLight

Patients

Laser Type (W)

Follow-up (months)

 IPSS 

 QoL 

  Qmax  

  PVR  

   PSA   

Bouchier-Hayes4

59

80

12

25 → 9

5 → 2

8.8 → 18.6

129 → 22

NA

Mohanty5

60

80

12

20 → 6

4 → 2

7.4 → 20.1

146 → 24

2.5 → NA

Al- Ansari6

10

80

36

27 → 10

NA

6.9 → 17

53 → 11

2.6 → 1.5

Pereira-Coreia7

10

120

24

22 → 7

NA

10 → 20.5

150 → 4

NA

Capitán8

50

120

24

24 → 8

5 → 1

8.0 → 23

NA

3.7 → 2.1

Kumar9

50

120

12

20 → 7

4 → 2

6.7 → 19.6

143 → 31

2.4 → NA

Lukacs10

69

120

12

22 → 6

NA

90 → 0

90 → 0

2.4 → 1.8

Bachmann1

136

180

6

21 → 7

5 → 2

9.5 → 23.3

110 → 38

2.7 → 1.4

IPSS, QOL, Qmax, PVR and PSA data values are presented as mean preoperative values and mean value at last follow-up.
Top